Moody Aldrich Partners LLC purchased a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,180 shares of the biopharmaceutical company’s stock, valued at approximately $1,739,000. Several other hedge funds and other institutional investors have […]
NJ State Employees Deferred Compensation Plan acquired a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,500 shares of the biopharmaceutical company’s stock, valued at approximately $363,000. Other institutional investors and […]
StockNews.com downgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) from a hold rating to a sell rating in a report issued on Thursday morning. MDGL has been the subject of several other research reports. Oppenheimer lifted their price objective on shares of Madrigal Pharmaceuticals from $300.00 to $350.00 in a research note on Tuesday, […]
StockNews.com downgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) from a hold rating to a sell rating in a research report sent to investors on Thursday morning. Several other equities research analysts have also recently weighed in on the company. Oppenheimer increased their target price on Madrigal Pharmaceuticals from $300.00 to $350.00 in a […]